Adial Pharmaceuticals Inc (ADIL) USD 0.001
Sell:$0.71Buy:$0.72
$0.03
(5.09%)
- This stock can be held in a
Stocks and Shares ISA$0.03
(5.09%)$0.03
(5.09%)Company Information
About this company
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Key people
Key facts
- EPICADIL
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS00688A2050
- Market cap$4.50m
- Employees5
- Shares in issue6.57m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.